Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• Functional Class and Six-Minute Walk Distance (6MWD) Improvement: Selexipag improved World Health Organization (WHO) functional class (FC) with an odds ratio of 0.564 (95% confidence interval (CI): 0.457-0.697) and significantly increased 6MWD, with a mean difference of 24.20 m (95% CI: 10.74-37.67), particularly after more than 6 months of treatment (mean difference (MD): 40.87 m, 95% CI: 10.97-70.77).
• Clinical Worsening Reduction and Pulmonary Vascular Resistance (PVR): Selexipag reduced the risk of clinical worsening by 39% when compared to placebo and significantly improved PVR in patients.
• Cardiac Index (CI) and N-terminal pro B-type natriuretic peptide (NT-proBNP) Levels: Selexipag led to a mean improvement in CI (MD: 0.47 L/min/m², 95% CI: 0.17-0.77), with notable improvements even at moderate dosages and within 6 months of treatment; it also improved NT-proBNP levels significantly over extended treatment durations (standardized mean difference (SMD): -0.61, 95% CI: -1.17 to -0.05).
• There is no safety information available in the reviewed studies.
• The reviewed studies included patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH), with subgroups of systemic sclerosis (59%), systemic lupus erythematosus (20%), and other connective tissue diseases (21%); maintained doses of selexipag (low, medium, high) showed favorable effects on 6MWD, WHO functional class, NT-proBNP, and cardiac index, particularly with treatment exceeding six months.